ASCO 2022 | mFOLFOXIRI/PAN vs mFOLFOX6/PAN as initial treatment of patients with unresectable RAS & BRAF WT mCRC

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, provides an overview of the results of the Phase III TRIPLETE (NCT03231722) study which evaluated modified FOLFOXIRI plus panitumumab versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC). The intensification of the upfront chemotherapy backbone in combination with EGFR inhibition in molecularly selected and mostly left-sided mCRC did not provide any benefit in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.